Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients
NCT00349388 · Annette Langseder · NA · terminated · last registry update 2019-01-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “none enrolled in second arm, therfore no analysis” | – | Registry record, Annette Langseder |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALOX5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-18Results posted on the registry: Shire, MMX Mesalamine/Mesalazine (Low Dose) + MMX Mesalamine/Mesalazine (High Dose) (NCT02093663)
- 2020-01-18Also stopped (terminated): VSL Pharmaceuticals, Mesalamine + Placebo (NCT03415711)
- 2019-11-18Also stopped (terminated): University of Minnesota, Zileuton + Placebo (NCT00493974)
- 2019-11-01Results posted on the registry: Bausch Health Americas, Inc., Encapsulated Mesalamine Granules (eMG) (NCT00326209)
- 2019-10-15Results posted on the registry: Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-10-15Also stopped (terminated): Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-09-06Results posted on the registry: Bausch Health Americas, Inc., Budesonide MMX® + Placebo (NCT01532648)
- 2019-08-28Results posted on the registry: Connecticut Children's Medical Center, Mesalazine + IV Corticosteroid (NCT01536535)
- 2019-08-28Results posted on the registry: Forest Laboratories, MAX-002 + Placebo (NCT01016262)
- 2019-08-28Also stopped (terminated): Forest Laboratories, MAX-002 + Placebo (NCT01016262)
- 2019-05-14Results posted on the registry: University of Nebraska, Leflunomide + Methotrexate-Sulfasalazine-Hydroxychloroquine (NCT00579878)
- 2019-04-18Also stopped (terminated): Christoph Gasche, mesalamine 2400 MG (5-ASA) + mesalamine 1200 MG (NCT03070574)
- 2019-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, Meclofenamic acid + Pentosan polysulfate sodium (NCT02930005)
- 2019-01-15Phase 3 first posted: Guangzhou First People's Hospital, 5-Aminosalicylic acid(5-ASA) and/or Prednisone (NCT03804931)
- 2018-12-10Results posted on the registry: P. Verschueren, Methotrexate + Sulfasalazine (NCT01172639)
- 2018-11-13Results posted on the registry: Hoffmann-La Roche, Azathioprine + Chloroquine (NCT01941095)
- 2018-10-23Phase 3 first posted: Dayanand Medical College and Hospital, Fecal Microbiota Transplantation + Mesalamine Granules (NCT03716388)
- 2018-09-06Phase 3 first posted: Astellas Pharma China, Inc., Peficitinib + Plaebo (NCT03660059)
- 2018-08-22Results posted on the registry: Massachusetts General Hospital, Sulfasalazine + placebo (NCT01667029)
- 2018-08-22Also stopped (terminated): Massachusetts General Hospital, Sulfasalazine + placebo (NCT01667029)
- 2018-08-08Results posted on the registry: Tillotts Pharma AG, TP05 + Asacol 400 mg (NCT01903252)
- 2018-04-17Results posted on the registry: University of North Carolina, Chapel Hill, Methotrexate (NCT01393405)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2018-01-30Results posted on the registry: Sanofi, Sarilumab + Sulfasalazine (NCT02373202)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision